-
Hydroxychloroquine reduces the death rate
-
Henry Ford healthcare test reports show
-
Tried over 2500 patients with results
-
This medicine saved many lives
Representative
New Delhi: Despite frequent controversies, the utility of hydroxychloroquine has
finally been certified in the US. In fact, it was immediately denied by the World
Health Organization after US President Donald Trump advocated it. This rebuttal
led to a major controversy. Later in India, ICMR also rejected its usefulness. A
large section of scientists was continuously investigating the effect of this drug on
corona patients, even after constant publicity. Now scientists at the Henry Ford
Health Service in Michigan have suggested that the drug is capable of keeping the
death toll from corona low. This medicine is especially effective on patients who
have less infection with corona virus. Under this, scientists have concluded this
after research on 2541 patients admitted to the hospitals there. This figure for
patients is from 10 March to 2 May. Dr. Steven Kalkanis, CEO of Henry Ford
Medical Group, associated with this research, said that our data is showing that
the use of this hydroxychloroquine was effective on patients and because of that
we have been able to reduce the death toll. He made it clear that there has been a
lot of controversy on the issue of the use of this drug, but now we are making the
findings public based on our research data. The research data of this health center
suggests that the death rate of people who were given this drug was 13 percent,
while 26.4 percent of the patients admitted without treatment received it in their
cheeks.
Despite frequent controversies research result finally came
some were given only this medicine. The World Health Organization was the first
to deny it when the US President spoke about this drug used for treatment of
malaria. Since then, the relationship between the US and the World Health
Organization continued to deteriorate. Mr. Trump had even said that this
institution called WHO is now working at the behest of China. An article about
this research by Henry Ford Health Organization has been published in the
International Scientific Research Journal, citing the data of his research, despite
WHO and others were against it.
According to the data, all the patients who came under the purview of this
research were aged above 18 years. Out of these, those brought under the purview
of this medicine were given this medicine only after admission to the hospital.
Despite being surrounded by constant controversies, a section of scientists were
themselves in favor of investigating it. Scientists from the Henry Ford Health
Organization were also among those with such opinions. Of the patients admitted
for treatment in the hospital, 91 percent of the patients were given this medicine
within 48 hours. Two doses of 400 mg were given to such patients on the first day
of treatment. After that, for two to five days, he was given two doses of two
hundred milligrams. Some patients also received a dose of five hundred
milligrams of azithromycin. This additional drug was administered in the dosage
of 350 mg for the next four days.
Patients were given complete information about drug
controversial drug hydroxychloroquine, was given only to patients who had heart
problems. After making the findings of the research public, Dr. Kalkanis said that
in his understanding this drug could definitely reduce the death toll among
patients suffering from corona. Dr. Marcus Xervos of the same institute said that
now the usefulness of the drug has been revealed and its benefit figures are also
before us. After this report, the American Food and Drug Administration (FDA)
may also revise its directive, which instructed to use disputes such as
hydroxychloroquine with considerable consideration. This American institution
said that it is not a corona drug. But now claims of lower death figures and survey
figures have come out.
Be First to Comment